medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2026, Número 4

<< Anterior Siguiente >>

Cir Card Mex 2026; 11 (4)


Tumor neuroendocrino pulmonar: reporte de casos

Jiménez-González RJ, Ogaz-Escarpita MC, Guillén-Ramírez RM, Marmolejo-Rivera R, García-Villarreal OA

Idioma: Ingles.
Referencias bibliográficas: 17
Paginas: 166-170
Archivo PDF: 2048.58 Kb.


RESUMEN

Las neoplasias neuroendocrinas pulmonares (NEN) se definen como un conjunto de tumores pulmonares que muestran morfología e inmunofenotipo neuroendocrinos. Suelen ser neoplasias de crecimiento lento y con sintomatología poco especifica. Se presentan dos casos clínicos de NEN abordadas mediante toracoscopia videoasistida y mini toracotomía anterior, con posterior diagnostico especifico mediante histopatología e inmunohistoquímica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ito T, Hijioka S, Masui T, et al. Advances in the diagnosis andtreatment of pancreatic neuroendocrine neoplasms in Japan. JGastroenterol. 2017;52(1):9-18. doi: 10.1007/s00535-016-1250-9.

  2. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHOclassification of neuroendocrine neoplasms. Endocr Pathol.2022;33(1):115-154. doi: 10.1007/s12022-022-09708-2.

  3. Vocino TG, Righi L, Volante M, Papotti M. Updates on lungneuroendocrine neoplasm classification. Histopathology.2024;84(1):67-85. doi: 10.1111/his.15058.

  4. Hung YP. Neuroendocrine tumors of the lung: updates and diagnosticpitfalls. Surg Pathol Clin. 2019;12(4):1055-1071. doi: 10.1016/j.path.2019.08.012.

  5. Karnan A. A rare neuroendocrine tumor of the lung. Pan Afr Med J.2023;46:54. doi: 10.11604/pamj.2023.46.54.41283.

  6. Dasari A, Shen C, Halperin D, et al. Trends in the incidence,prevalence, and survival outcomes in patients with neuroendocrinetumors in the United States. JAMA Oncol. 2017;3(10):1335-1342.doi: 10.1001/jamaoncol.2017.0589

  7. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoidtumors. Cancer. 2003;97(4):934-959. doi: 10.1002/cncr.11105.

  8. Tomita T. Significance of chromogranin A and synaptophysinin pancreatic neuroendocrine tumors. Bosn J Basic Med Sci.2020;20(3):336-346. doi: 10.17305/bjbms.2020.4632.

  9. Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, PapamichaelD, Kountourakis P. Chromogranin A as a valid marker in oncology:Clinical application or false hopes? World J Methodol. 2017;7(1):9-15. doi: 10.5662/wjm.v7.i1.9.

  10. Kriegsmann K, Zgorzelski C, Muley T, et al. Role of synaptophysin,chromogranin and CD56 in adenocarcinoma and squamous cellcarcinoma of the lung lacking morphological features of neuroendocrinedifferentiation: a retrospective large-scale study on 1,170 tissue samples.BMC Cancer. 2021;21(1):486. doi: 10.1186/s12885-021-08140-9.

  11. Moller K, Uhlig R, Gorbokon N, et al. Comparison of INSM1immunostaining with established neuroendocrine markerssynaptophysin and chromogranin A in over 14,000 neuroendocrine andnon-neuroendocrine tumors. Mol Cell Endocrinol. 2024;581:112106.doi: 10.1016/j.mce.2023.112106.

  12. Sakakibara R, Kobayashi M, Takahashi N, et al. Insulinoma-associatedProtein 1 (INSM1) Is a Better Marker for the Diagnosis and PrognosisEstimation of Small Cell Lung Carcinoma Than Neuroendocrine PhenotypeMarkers Such as Chromogranin A, Synaptophysin, and CD56. Am J SurgPathol. 2020;44(6):757-764. doi: 10.1097/PAS.0000000000001444.

  13. Iso H, Hisakane K, Mikami E, et al. Thyroid transcription factor-1(TTF-1) expression and the efficacy of combination therapy withimmune checkpoint inhibitors and cytotoxic chemotherapy in nonsquamousnon-small cell lung cancer. Transl Lung Cancer Res.2023;12(9):1850-1861. doi: 10.21037/tlcr-23-331.

  14. Verset L. TTF-1 positive small cell cancers: Don’t think they’re alwaysprimary pulmonary! World J Gastrointest Oncol. 2011;3(10):144. doi:10.4251/wjgo.v3.i10.144.

  15. Xie B, Sui T, Qin Y, Miao S, Jiao W. [Comparison of Short-termOutcomes of Lung Segmentectomy by Robotic-assisted and VideoassistedThoracoscopic Surgery]. Zhongguo Fei Ai Za Zhi ChinJ Lung Cancer. 2019;22(12):767-771. doi: 10.3779/j.issn.1009-3419.2019.12.06.

  16. Ma J, Li X, Zhao S, Wang J, Zhang W, Sun G. Robot-assisted thoracicsurgery versus video-assisted thoracic surgery for lung lobectomy orsegmentectomy in patients with non-small cell lung cancer: a metaanalysis.BMC Cancer. 2021;21(1):498. doi: 10.1186/s12885-021-08241-5.

  17. Kidane B, Bott M, Spicer J, et al. The American Association forThoracic Surgery (AATS) 2023 expert consensus document: stagingand multidisciplinary management of patients with early-stage nonsmallcell lung cancer. J Thorac Cardiovasc Surg. 2023;166(3):637-654. doi: 10.1016/j.jtcvs.2023.04.039.




2020     |     www.medigraphic.com